Home
Resources
Publications
Identification of Novel Therapeutic Targets in Acute Leukemias With NRAS Mutations Using a Pharmacologic Approach

Identification of Novel Therapeutic Targets in Acute Leukemias With NRAS Mutations Using a Pharmacologic Approach

Atsushi Nonami, Martin Sattler, Ellen Weisberg, Qingsong Liu, Jianming Zhang, Matthew P Patricelli, Amanda L Christie, Amy M Saur, Nancy E Kohl, Andrew L Kung, Hojong Yoon, Taebo Sim, Nathanael S Gray, etc.

Blood. 2015 May 14;125(20):3133-43.

PMID: 25833960

Abstract:

Oncogenic forms of NRAS are frequently associated with hematologic malignancies and other cancers, making them important therapeutic targets. Inhibition of individual downstream effector molecules (eg, RAF kinase) have been complicated by the rapid development of resistance or activation of bypass pathways. For the purpose of identifying novel targets in NRAS-transformed cells, we performed a chemical screen using mutant NRAS transformed Ba/F3 cells to identify compounds with selective cytotoxicity. One of the compounds identified, GNF-7, potently and selectively inhibited NRAS-dependent cells in preclinical models of acute myelogenous leukemia and acute lymphoblastic leukemia. Mechanistic analysis revealed that its effects were mediated in part through combined inhibition of ACK1/AKT and of mitogen-activated protein kinase kinase kinase kinase 2 (germinal center kinase). Similar to genetic synthetic lethal approaches, these results suggest that small molecule screens can be used to identity novel therapeutic targets in cells addicted to RAS oncogenes.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP839706079	GNF-7		839706-07-9	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: